MCID: TCL005
MIFTS: 52

T-Cell Prolymphocytic Leukemia

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for T-Cell Prolymphocytic Leukemia

MalaCards integrated aliases for T-Cell Prolymphocytic Leukemia:

Name: T-Cell Prolymphocytic Leukemia 59 29 6 73
T-Cell Chronic Lymphocytic Leukemia 59
Lymphocytic Leukemia T-Cell Chronic 55
Leukemia, T-Cell, Chronic 73
T-Pll 59

Characteristics:

Orphanet epidemiological data:

59
t-cell prolymphocytic leukemia
Age of onset: Adult;

Classifications:



External Ids:

Orphanet 59 ORPHA86871
UMLS via Orphanet 74 C0023494 C2363142
MESH via Orphanet 45 D015461
ICD10 via Orphanet 34 C91.6
ICD10 33 C91.6

Summaries for T-Cell Prolymphocytic Leukemia

MalaCards based summary : T-Cell Prolymphocytic Leukemia, also known as t-cell chronic lymphocytic leukemia, is related to prolymphocytic leukemia and b-cell lymphomas. An important gene associated with T-Cell Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are ERK Signaling and TCR Signaling (Qiagen). The drugs Vidarabine and alemtuzumab have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone and bone marrow, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 76 T-cell-prolymphocytic leukemia (T-PLL) is a mature T-cell leukemia with aggressive behavior and... more...

Related Diseases for T-Cell Prolymphocytic Leukemia

Diseases in the B Cell Prolymphocytic Leukemia family:

T-Cell Prolymphocytic Leukemia

Diseases related to T-Cell Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 48)
# Related Disease Score Top Affiliating Genes
1 prolymphocytic leukemia 32.9 ATM MTCP1 MYC TCL1A
2 b-cell lymphomas 29.8 CDKN1B MS4A1 MYC TCL1A
3 t-cell leukemia 29.4 CD7 MTCP1 MYC TCL1A
4 leukemia 11.0
5 large cell carcinoma with rhabdoid phenotype 10.4 SMARCB1 VEGFA
6 lymphoma 10.4
7 pityriasis lichenoides 10.3 CD7 MS4A1
8 primary effusion lymphoma 10.2 MYC TCL1A VEGFA
9 jak3-deficient severe combined immunodeficiency 10.2 JAK1 JAK3
10 autoimmune lymphoproliferative syndrome, type v 10.1
11 diffuse large b-cell lymphoma 10.1
12 large granular lymphocyte leukemia 10.1
13 leukemia, chronic lymphocytic 2 10.1
14 t-cell large granular lymphocyte leukemia 10.1
15 leukemia, b-cell, chronic 10.1
16 kaposi sarcoma 10.1
17 leukemia, chronic lymphocytic 10.1
18 sarcoma 10.1
19 ataxia-telangiectasia 10.1
20 nervous system cancer 10.0 CDKN1B MYC SMARCB1
21 infantile liver failure syndrome 1 9.9
22 palmoplantar keratosis 9.9
23 retinitis 9.9
24 acute liver failure 9.9
25 thyroiditis 9.9
26 vasculitis 9.9
27 type i 9.9
28 peripheral t-cell lymphoma 9.9
29 breast cancer 9.9
30 endotheliitis 9.9
31 prostate cancer 9.9
32 panuveitis 9.9
33 scleritis 9.9
34 nijmegen breakage syndrome 9.9
35 anterior scleritis 9.9
36 myocardial infarction 9.9
37 prostatitis 9.9
38 gastric cancer 9.9
39 purpura 9.9
40 lymphoblastic leukemia, acute, with lymphomatous features 9.9 ABL1 JAK1 JAK3
41 lactocele 9.8 JAK1 JAK3
42 mantle cell lymphoma 9.7 ATM CDKN1B MYC
43 polycythemia vera 9.6 ABL1 JAK1 JAK3
44 lymphoblastic leukemia 9.6 ABL1 ATM JAK1 JAK3
45 precursor t-cell acute lymphoblastic leukemia 9.4 ABL1 CD7 MYC TCL1A
46 lymphoma, non-hodgkin, familial 8.6 ATM CD52 CDKN1B MS4A1 MYC TCL1A
47 hematologic cancer 8.6 ABL1 ATM CD7 CDKN1B MYC VEGFA
48 ovarian cancer 8.3 ABL1 ATM CDKN1B CHEK2 MYC VEGFA

Graphical network of the top 20 diseases related to T-Cell Prolymphocytic Leukemia:



Diseases related to T-Cell Prolymphocytic Leukemia

Symptoms & Phenotypes for T-Cell Prolymphocytic Leukemia

GenomeRNAi Phenotypes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

26 (show all 42)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00221-A-1 10.35 ABL1 MYC SMARCB1
2 Decreased viability GR00221-A-2 10.35 ABL1 CHEK2 SMARCB1
3 Decreased viability GR00221-A-3 10.35 ABL1 ATM CHEK2 JAK3 MYC SMARCB1
4 Decreased viability GR00221-A-4 10.35 ATM CHEK2
5 Decreased viability GR00342-S-1 10.35 ABL1
6 Decreased viability GR00342-S-2 10.35 CHEK2 ABL1
7 Decreased viability GR00342-S-3 10.35 ABL1
8 Decreased viability GR00381-A-1 10.35 SMARCB1
9 Decreased viability GR00402-S-2 10.35 ATM CHEK2 JAK3 MYC SMARCB1 ABL1
10 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.31 SMARCB1 ABL1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.31 JAK3 ATM ABL1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.31 SMARCB1 ATM JAK3
13 Increased shRNA abundance (Z-score > 2) GR00366-A-114 10.31 ATM CHEK2
14 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.31 CHEK2
15 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.31 SMARCB1 ATM
16 Increased shRNA abundance (Z-score > 2) GR00366-A-123 10.31 CHEK2 ABL1
17 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.31 JAK3 ATM
18 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.31 ABL1 ATM
19 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.31 ABL1
20 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.31 ATM
21 Increased shRNA abundance (Z-score > 2) GR00366-A-16 10.31 ATM
22 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.31 SMARCB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-194 10.31 SMARCB1
24 Increased shRNA abundance (Z-score > 2) GR00366-A-195 10.31 JAK3
25 Increased shRNA abundance (Z-score > 2) GR00366-A-207 10.31 CHEK2
26 Increased shRNA abundance (Z-score > 2) GR00366-A-214 10.31 ATM
27 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.31 ATM
28 Increased shRNA abundance (Z-score > 2) GR00366-A-3 10.31 ABL1
29 Increased shRNA abundance (Z-score > 2) GR00366-A-30 10.31 ABL1
30 Increased shRNA abundance (Z-score > 2) GR00366-A-41 10.31 ATM
31 Increased shRNA abundance (Z-score > 2) GR00366-A-43 10.31 JAK3 ABL1
32 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.31 ABL1
33 Increased shRNA abundance (Z-score > 2) GR00366-A-6 10.31 JAK3
34 Increased shRNA abundance (Z-score > 2) GR00366-A-8 10.31 ATM
35 Increased shRNA abundance (Z-score > 2) GR00366-A-81 10.31 ATM
36 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.31 SMARCB1 ABL1
37 Increased shRNA abundance (Z-score > 2) GR00366-A-85 10.31 SMARCB1 CHEK2 JAK3 ABL1 ATM
38 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.31 JAK3
39 Decreased human cytomegalovirus (HCMV) strain AD169 replication GR00248-A 9.72 ABL1 ATM CHEK2 JAK1 JAK3
40 Decreased Hepatitis C Virus pseudoparticles (HCVpp; H77; genotype 1a) infection GR00234-A-1 9.54 ATM CDKN1B JAK1
41 Increased viability with MLN4924 (a NAE inhibitor) GR00250-A-3 9.17 ABL1 ATM BRCC3 C11orf65 CDKN1B CHEK2
42 Decreased viability in HMC1.1 cells GR00105-A-0 9.16 JAK1 JAK3

MGI Mouse Phenotypes related to T-Cell Prolymphocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.03 CHEK2 JAK1 JAK3 MS4A1 MYC NFKB1
2 endocrine/exocrine gland MP:0005379 10.02 NFKB1 VEGFA ABL1 ATM CD7 CDKN1B
3 immune system MP:0005387 9.93 ABL1 ATM CD7 CDKN1B CHEK2 JAK1
4 digestive/alimentary MP:0005381 9.91 ABL1 CDKN1B JAK3 MYC NFKB1 SMARCB1
5 liver/biliary system MP:0005370 9.5 ABL1 CDKN1B JAK1 MYC NFKB1 SMARCB1
6 neoplasm MP:0002006 9.1 ATM CDKN1B CHEK2 MYC SMARCB1 VEGFA

Drugs & Therapeutics for T-Cell Prolymphocytic Leukemia

Drugs for T-Cell Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 53)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vidarabine Approved, Investigational Phase 2,Phase 1 24356-66-9 32326 21704
2
alemtuzumab Approved, Investigational Phase 2 216503-57-0
3
Fludarabine Approved Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
4
Miconazole Approved, Investigational, Vet_approved Phase 2,Phase 1 22916-47-8 4189
5
Cyclophosphamide Approved, Investigational Phase 2,Phase 1 50-18-0, 6055-19-2 2907
6
Mycophenolic acid Approved Phase 2,Phase 1 24280-93-1 446541
7
Mitoxantrone Approved, Investigational Phase 2 65271-80-9 4212
8
Mycophenolate mofetil Approved, Investigational Phase 2,Phase 1 128794-94-5 5281078
9
Etoposide Approved Phase 2,Phase 1 33419-42-0 36462
10
Mechlorethamine Approved, Investigational Phase 2,Phase 1 51-75-2 4033
11
Cytarabine Approved, Investigational Phase 2,Phase 1 147-94-4 6253
12
Everolimus Approved Phase 2,Phase 1 159351-69-6 6442177
13
Tacrolimus Approved, Investigational Phase 2 104987-11-3 445643 439492
14
Melphalan Approved Phase 2,Phase 1 148-82-3 4053 460612
15
Sirolimus Approved, Investigational Phase 2,Phase 1 53123-88-9 5284616 6436030 46835353
16
Carmustine Approved, Investigational Phase 2,Phase 1 154-93-8 2578
17
Bortezomib Approved, Investigational Phase 2,Phase 1 179324-69-7 387447 93860
18
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
19 Analgesics Phase 2
20 Alkylating Agents Phase 2,Phase 1
21 Cyclosporins Phase 2,Phase 1
22 Topoisomerase Inhibitors Phase 2,Phase 1
23 Dermatologic Agents Phase 2,Phase 1
24 Vidarabine Phosphate Phase 2,Phase 1
25 Peripheral Nervous System Agents Phase 2
26 Anti-Bacterial Agents Phase 2,Phase 1
27 Antibiotics, Antitubercular Phase 2,Phase 1
28 Immunosuppressive Agents Phase 2,Phase 1
29 Anti-Infective Agents Phase 2,Phase 1
30 Antifungal Agents Phase 2,Phase 1
31 Antitubercular Agents Phase 2,Phase 1
32 Antirheumatic Agents Phase 2,Phase 1
33 Antimetabolites Phase 2,Phase 1
34 Antiviral Agents Phase 2,Phase 1
35 Antimetabolites, Antineoplastic Phase 2,Phase 1
36 Calcineurin Inhibitors Phase 2,Phase 1
37 Antineoplastic Agents, Alkylating Phase 2,Phase 1
38 Podophyllotoxin Phase 2,Phase 1 518-28-5
39 Nitrogen Mustard Compounds Phase 2,Phase 1
40 Etoposide phosphate Phase 2,Phase 1
41 Keratolytic Agents Phase 2,Phase 1
42 Antimitotic Agents Phase 2,Phase 1
43 Antineoplastic Agents, Phytogenic Phase 2,Phase 1
44 phenylalanine Nutraceutical Phase 2,Phase 1
45 alanine Nutraceutical Phase 2,Phase 1
46
Niraparib Approved, Investigational Phase 1 1038915-60-4 24958200
47
Busulfan Approved, Investigational Phase 1 55-98-1 2478
48
Romidepsin Approved, Investigational Phase 1 128517-07-7 5352062
49 Poly(ADP-ribose) Polymerase Inhibitors Phase 1
50 Antilymphocyte Serum Phase 1

Interventional clinical trials:

(show all 14)
# Name Status NCT ID Phase Drugs
1 Combined Immunochemotherapy in Patients With T-Prolymphocytic Leukemia (T-PLL) Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
2 Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
3 CAR-pNK Cell Immunotherapy in CD7 Positive Leukemia and Lymphoma Recruiting NCT02742727 Phase 1, Phase 2
4 Sirolimus, Cyclosporine, and Mycophenolate Mofetil in Preventing Graft-versus-Host Disease in Treating Patients With Blood Cancer Undergoing Donor Peripheral Blood Stem Cell Transplant Recruiting NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
5 Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Recruiting NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
6 Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma Active, not recruiting NCT00005803 Phase 1, Phase 2 Carmustine;Cyclophosphamide;Cyclosporine;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil
7 5-Azacytidine (Azacytidine; Vidaza) in Chronic Lymphocytic Leukemia Terminated NCT00413478 Phase 2 5-Azacytidine
8 Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia Withdrawn NCT01162031 Phase 2 Velcade
9 A Study of MK4827 in Participants With Advanced Solid Tumors or Hematologic Malignancies (MK-4827-001 AM8) Completed NCT00749502 Phase 1 MK-4827
10 Safety and Dose Study of GRN163L to Treat Patients With Chronic Lymphoproliferative Disease(CLD) Completed NCT00124189 Phase 1 GRN163L
11 Romidepsin Maintenance After Allogeneic Stem Cell Transplantation Recruiting NCT02512497 Phase 1 Romidepsin;Busulfan;Fludarabine;Thymoglobulin
12 Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Nelarabine in Patients With Relapsed/Refractory Lymphoid Malignancies Active, not recruiting NCT01094860 Phase 1 Nelarabine
13 Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma Terminated NCT00671112 Phase 1 Bortezomib;Everolimus
14 Registry of the German CLL Study Group Recruiting NCT02863692

Search NIH Clinical Center for T-Cell Prolymphocytic Leukemia

Genetic Tests for T-Cell Prolymphocytic Leukemia

Genetic tests related to T-Cell Prolymphocytic Leukemia:

# Genetic test Affiliating Genes
1 T-Cell Prolymphocytic Leukemia 29

Anatomical Context for T-Cell Prolymphocytic Leukemia

MalaCards organs/tissues related to T-Cell Prolymphocytic Leukemia:

41
T Cells, Bone, Bone Marrow, Skin, Liver, Spleen, Lymph Node

Publications for T-Cell Prolymphocytic Leukemia

Articles related to T-Cell Prolymphocytic Leukemia:

(show top 50) (show all 150)
# Title Authors Year
1
T-cell prolymphocytic leukemia negative for surface CD3 and CD45. ( 29976781 )
2018
2
Exploring the molecular pathogenesis associated with T-cell prolymphocytic leukemia based on a comprehensive bioinformatics analysis. ( 29928415 )
2018
3
Patient-Customized Drug Combination Prediction and Testing for T-cell Prolymphocytic Leukemia Patients. ( 29483097 )
2018
4
SAMHD1 is recurrently mutated in T-cell prolymphocytic leukemia. ( 29352181 )
2018
5
Allogeneic hematopoietic cell transplantation in T-cell prolymphocytic leukemia: A single-center experience. ( 29407180 )
2018
6
Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia. ( 28194886 )
2017
7
The distinctive cytological features of T-cell prolymphocytic leukemia. ( 28120343 )
2017
8
T-cell Prolymphocytic Leukemia. ( 28340878 )
2017
9
First-in-human response of BCL-2 inhibitor venetoclax in T-cell prolymphocytic leukemia. ( 28972014 )
2017
10
Linear nonpalpable purpura in a young male: a unique presentation of leukemia cutis in T-cell prolymphocytic leukemia. ( 28083939 )
2017
11
Comparison of clinicopathological characteristics between T-cell prolymphocytic leukemia and peripheral T-cell lymphoma, not otherwise specified. ( 28129454 )
2017
12
Advances in the understanding and management of T-cell prolymphocytic leukemia. ( 29262669 )
2017
13
Modified Hyper-CVAD Regimen Followed by Autologous Peripheral Blood Stem Cell Transplantation Successfully Treated Synchronous T-Cell Prolymphocytic Leukemia and Gastric Cancer in a 68-Year-Old Female. ( 28824253 )
2017
14
T-cell prolymphocytic leukemia and tuberculosis: a puzzling association. ( 28878921 )
2017
15
TCL-1-positive hematogones in a patient with T-cell prolymphocytic leukemia after therapy. ( 28232160 )
2017
16
Characteristics, outcomes, prognostic factors and treatment of patients with T-cell prolymphocytic leukemia (T-PLL). ( 28379307 )
2017
17
T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib). ( 29296924 )
2017
18
Small Cell Variant of T-Cell Prolymphocytic Leukemia with Acquired Palmoplantar Keratoderma and Cutaneous Infiltration. ( 26813734 )
2016
19
Bullous leukemia cutis in a patient with T-cell prolymphocytic leukemia. ( 27504481 )
2016
20
Intraocular T-cell Prolymphocytic Leukemia Masquerading as Necrotizing Herpetic Retinitis. ( 27736276 )
2016
21
Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL). ( 25888568 )
2015
22
A pediatric case of T-cell prolymphocytic leukemia. ( 25417638 )
2015
23
T-Cell Prolymphocytic Leukemia, Small Cell Variant, Possibly at the Stage of Intracytoplasmic Expression of CD3 in T-Cell Ontogenesis. ( 26106002 )
2015
24
Epigenetic therapy overcomes treatment resistance in T cell prolymphocytic leukemia. ( 26109102 )
2015
25
Expression of S100 Protein in CD4-positive T-cell Lymphomas Is Often Associated With T-cell Prolymphocytic Leukemia. ( 26379148 )
2015
26
T-cell prolymphocytic leukemia presenting with leukemic serous effusion in a prostate cancer patient. ( 26881553 )
2015
27
Are we improving the outcome for patients with T-cell prolymphocytic leukemia by allogeneic stem cell transplantation? ( 25712069 )
2015
28
T-cell chronic lymphocytic leukemia or small-cell variant of T-cell prolymphocytic leukemia: a historical perspective and search for consensus. ( 25846234 )
2015
29
Survival trends in T cell prolymphocytic leukemia: A SEER database analysis. ( 26292711 )
2015
30
T-cell prolymphocytic leukemia: survival improves with alemtuzemab, but stem cell transplant eligibility 'counts' even more. ( 26293613 )
2015
31
Encephalitozoon hellem in a patient with CD4(+) T-cell prolymphocytic leukemia: case report and genomic identification. ( 26299583 )
2015
32
A T-cell prolymphocytic leukemia case with central nervous system involvement. ( 26550397 )
2015
33
Identification of a novel SEPT9-ABL1 fusion gene in a patient with T-cell prolymphocytic leukemia. ( 25068103 )
2014
34
T-cell prolymphocytic leukemia in a 63-year-old female with a pre-existing T-cell large granular lymphocytic leukemia: Metachronous T-cell leukemias with discordant subset restrictions (CD4 versus CD8) and distinct clonal identities. ( 25238936 )
2014
35
Infiltration of the thyroid gland by T-cell prolymphocytic leukemia. ( 24762052 )
2014
36
T-cell prolymphocytic leukemia with extensive cardiovascular infiltrate leading to multiple myocardial infarctions and cardiac death. ( 25593528 )
2014
37
Central nervous system involvement of T-cell prolymphocytic leukemia diagnosed with stereotactic brain biopsy: case report. ( 24764733 )
2014
38
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. ( 24825865 )
2014
39
T-cell Prolymphocytic Leukemia Frequently Shows Cutaneous Involvement and Is Associated With Gains of MYC, Loss of ATM, and TCL1A Rearrangement. ( 25310835 )
2014
40
Diffuse anterior scleritis and secondary glaucoma as a manifestation of adult T-cell prolymphocytic leukemia. ( 24977988 )
2014
41
Recurrent mutation of JAK3 in T-cell prolymphocytic leukemia. ( 24446122 )
2014
42
[Splenic rupture associated with aggressive conversion of indolent T-cell prolymphocytic leukemia]. ( 23676644 )
2013
43
Sequential chemoimmunotherapy of fludarabine, mitoxantrone, and cyclophosphamide induction followed by alemtuzumab consolidation is effective in T-cell prolymphocytic leukemia. ( 23512246 )
2013
44
Cutaneous presentation of T-cell prolymphocytic leukemia. ( 23513557 )
2013
45
Immunophenotypic characterization of T-cell prolymphocytic leukemia. ( 24124154 )
2013
46
Recurrent JAK1 and JAK3 somatic mutations in T-cell prolymphocytic leukemia. ( 24048415 )
2013
47
Coronary vasculitis associated with T-cell prolymphocytic leukemia. ( 23731632 )
2013
48
T-cell prolymphocytic leukemia (T-PLL) with overlapping cytomorphological features with T-CLL and T-ALL: a case initially diagnosed by fine-needle aspiration cytology and immunocytochemistry. ( 21987484 )
2013
49
T-cell prolymphocytic leukemia. ( 23382603 )
2013
50
Cost-effectiveness of alemtuzumab for T-cell prolymphocytic leukemia. ( 22980700 )
2012

Variations for T-Cell Prolymphocytic Leukemia

ClinVar genetic disease variations for T-Cell Prolymphocytic Leukemia:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 ATM NM_000051.3(ATM): c.7638_7646delTAGAATTTC (p.Arg2547_Ser2549del) deletion Pathogenic rs587776547 GRCh38 Chromosome 11, 108331887: 108331895
2 ATM NM_000051.3(ATM): c.7638_7646delTAGAATTTC (p.Arg2547_Ser2549del) deletion Pathogenic rs587776547 GRCh37 Chromosome 11, 108202614: 108202622
3 ATM NM_000051.3(ATM): c.7271T> G (p.Val2424Gly) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs28904921 GRCh37 Chromosome 11, 108199929: 108199929
4 ATM NM_000051.3(ATM): c.7271T> G (p.Val2424Gly) single nucleotide variant Pathogenic/Likely pathogenic,risk factor rs28904921 GRCh38 Chromosome 11, 108329202: 108329202
5 ATM NM_000051.3(ATM): c.5044G> C (p.Asp1682His) single nucleotide variant Pathogenic rs121434217 GRCh37 Chromosome 11, 108170479: 108170479
6 ATM NM_000051.3(ATM): c.5044G> C (p.Asp1682His) single nucleotide variant Pathogenic rs121434217 GRCh38 Chromosome 11, 108299752: 108299752
7 ATM NM_000051.3(ATM): c.5309C> G (p.Ser1770Ter) single nucleotide variant Pathogenic rs121434223 GRCh37 Chromosome 11, 108172506: 108172506
8 ATM NM_000051.3(ATM): c.5309C> G (p.Ser1770Ter) single nucleotide variant Pathogenic rs121434223 GRCh38 Chromosome 11, 108301779: 108301779

Copy number variations for T-Cell Prolymphocytic Leukemia from CNVD:

7 (show top 50) (show all 758)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14323 1 107060000 118270000 Deletion T-cell prolymphocytic leukemia
2 17205 1 141501392 142732360 Amplification T-cell prolymphocytic leukemia
3 19890 1 151880356 153088354 Deletion T-cell prolymphocytic leukemia
4 22015 1 164099958 164243756 Amplification T-cell prolymphocytic leukemia
5 24296 1 178292024 178520303 Amplification T-cell prolymphocytic leukemia
6 24451 1 180754716 183730500 Amplification T-cell prolymphocytic leukemia
7 25710 1 193462805 193618427 Deletion T-cell prolymphocytic leukemia
8 26226 1 198221297 245353397 Amplification T-cell prolymphocytic leukemia
9 29813 1 236310000 236970000 Deletion T-cell prolymphocytic leukemia
10 31149 1 25598247 25881984 Deletion T-cell prolymphocytic leukemia
11 31214 1 26102907 26624823 Deletion T-cell prolymphocytic leukemia
12 31215 1 26102907 26936965 Deletion T-cell prolymphocytic leukemia
13 31328 1 26860573 29239576 Deletion T-cell prolymphocytic leukemia
14 35233 1 6146230 6344245 Deletion T-cell prolymphocytic leukemia
15 35791 1 67452671 99313693 Deletion T-cell prolymphocytic leukemia
16 36896 1 825852 120863833 Amplification T-cell prolymphocytic leukemia
17 39073 10 108954534 111745117 Deletion T-cell prolymphocytic leukemia
18 39204 10 111824569 135311386 Amplification T-cell prolymphocytic leukemia
19 40780 10 133604797 135311386 Deletion T-cell prolymphocytic leukemia
20 41072 10 135165535 135311386 Amplification T-cell prolymphocytic leukemia
21 41217 10 148946 135311386 Amplification T-cell prolymphocytic leukemia
22 41219 10 148946 5692243 Deletion T-cell prolymphocytic leukemia
23 41413 10 17718148 22325377 Deletion T-cell prolymphocytic leukemia
24 41736 10 23032969 39064552 Deletion T-cell prolymphocytic leukemia
25 41964 10 26990000 30260000 Deletion T-cell prolymphocytic leukemia
26 42441 10 34110000 35980000 Deletion T-cell prolymphocytic leukemia
27 43355 10 46363383 47154881 Amplification T-cell prolymphocytic leukemia
28 44297 10 54778135 56318960 Deletion T-cell prolymphocytic leukemia
29 45076 10 67100000 71360000 Deletion T-cell prolymphocytic leukemia
30 46742 10 85720790 86922140 Deletion T-cell prolymphocytic leukemia
31 47214 10 90488702 94393578 Deletion T-cell prolymphocytic leukemia
32 48517 11 100045570 103051410 Deletion T-cell prolymphocytic leukemia
33 49138 11 10330000 11140000 Deletion T-cell prolymphocytic leukemia
34 49397 11 106417979 114849006 Deletion T-cell prolymphocytic leukemia
35 49494 11 107346114 107685623 Deletion T-cell prolymphocytic leukemia
36 49495 11 107346114 108015771 Deletion T-cell prolymphocytic leukemia
37 49502 11 107401046 107685623 Deletion T-cell prolymphocytic leukemia
38 49503 11 107419503 108193907 Deletion T-cell prolymphocytic leukemia
39 49515 11 107511257 108661992 Deletion T-cell prolymphocytic leukemia
40 49523 11 107598768 107745036 Deletion ATM T-cell prolymphocytic leukemia
41 49774 11 110891599 111596604 Deletion T-cell prolymphocytic leukemia
42 50371 11 117492601 119996648 Deletion T-cell prolymphocytic leukemia
43 50952 11 120493810 122186945 Deletion T-cell prolymphocytic leukemia
44 51031 11 122000000 131630000 Gain T-cell prolymphocytic leukemia
45 51124 11 123252803 123608170 Deletion T-cell prolymphocytic leukemia
46 51271 11 124529138 125115632 Deletion T-cell prolymphocytic leukemia
47 51421 11 125855565 126161131 Deletion T-cell prolymphocytic leukemia
48 51521 11 127437820 128227400 Deletion T-cell prolymphocytic leukemia
49 51526 11 127525578 128328976 Deletion T-cell prolymphocytic leukemia
50 51529 11 127550030 128131996 Deletion T-cell prolymphocytic leukemia

Expression for T-Cell Prolymphocytic Leukemia

Search GEO for disease gene expression data for T-Cell Prolymphocytic Leukemia.

Pathways for T-Cell Prolymphocytic Leukemia

Pathways related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.84 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3
2
Show member pathways
12.89 ATM CHEK2 JAK1 JAK3 NFKB1
3
Show member pathways
12.88 CDKN1B JAK1 JAK3 MYC NFKB1
4
Show member pathways
12.83 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
5
Show member pathways
12.78 ABL1 JAK1 JAK3 MYC NFKB1
6
Show member pathways
12.77 CDKN1B JAK1 JAK3 MYC NFKB1
7 12.76 ABL1 CDKN1B JAK1 JAK3 MYC NFKB1
8
Show member pathways
12.75 ATM CDKN1B JAK1 JAK3 VEGFA
9
Show member pathways
12.64 ATM CDKN1B JAK1 JAK3 MTCP1 MYC
10
Show member pathways
12.54 CDKN1B JAK1 MYC NFKB1 VEGFA
11
Show member pathways
12.51 CDKN1B JAK1 MYC NFKB1
12 12.49 ATM BRCC3 CDKN1B CHEK2
13 12.46 ABL1 ATM CDKN1B MYC NFKB1 VEGFA
14
Show member pathways
12.38 JAK1 JAK3 NFKB1 VEGFA
15
Show member pathways
12.36 ABL1 ATM CDKN1B CHEK2 MYC
16
Show member pathways
12.36 ABL1 CDKN1B JAK1 MYC NFKB1 VEGFA
17
Show member pathways
12.35 ABL1 ATM BRCC3 CHEK2
18 12.33 ABL1 ATM CDKN1B CHEK2 MYC
19 12.28 CDKN1B JAK1 JAK3 NFKB1
20 12.27 CDKN1B JAK1 JAK3 MYC NFKB1
21 12.25 ATM CHEK2 JAK1 JAK3 MYC NFKB1
22 12.23 ATM CDKN1B MYC NFKB1
23
Show member pathways
12.2 CDKN1B CHEK2 MYC NFKB1
24
Show member pathways
12.2 CDKN1B JAK1 JAK3 NFKB1 VEGFA
25 12.17 JAK1 MYC NFKB1 VEGFA
26
Show member pathways
12.14 JAK1 JAK3 MYC
27 12.14 ATM CHEK2 MYC NFKB1
28 11.96 JAK1 JAK3 MYC VEGFA
29
Show member pathways
11.94 JAK1 JAK3 MYC NFKB1
30 11.89 CDKN1B NFKB1 VEGFA
31 11.88 CDKN1B NFKB1 VEGFA
32
Show member pathways
11.85 JAK1 JAK3 NFKB1
33 11.85 CDKN1B MYC NFKB1
34 11.82 ABL1 CDKN1B MYC
35
Show member pathways
11.82 ABL1 ATM CHEK2
36
Show member pathways
11.79 ATM CHEK2 SMARCB1
37 11.78 ABL1 ATM CDKN1B MYC NFKB1
38 11.73 ATM CDKN1B MYC
39 11.69 CDKN1B JAK1 MYC
40
Show member pathways
11.68 JAK1 JAK3 MYC NFKB1
41 11.67 ATM CHEK2 MYC
42 11.62 ABL1 ATM CHEK2
43 11.59 ABL1 CDKN1B SMARCB1
45 11.54 JAK1 MYC NFKB1 VEGFA
46 11.52 ABL1 ATM CDKN1B MYC
47 11.49 JAK1 MYC NFKB1
48 11.48 ATM CHEK2 NFKB1
49 11.47 ABL1 ATM CDKN1B MYC NFKB1
50 11.46 CDKN1B MYC NFKB1 VEGFA

GO Terms for T-Cell Prolymphocytic Leukemia

Cellular components related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein-containing complex GO:0032991 9.35 ABL1 MTCP1 MYC SMARCB1 TCL1A
2 extrinsic component of cytoplasmic side of plasma membrane GO:0031234 8.8 ABL1 JAK1 JAK3

Biological processes related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 27)
# Name GO ID Score Top Affiliating Genes
1 regulation of apoptotic process GO:0042981 9.93 ABL1 ATM CHEK2 JAK3
2 cytokine-mediated signaling pathway GO:0019221 9.92 JAK1 JAK3 MYC VEGFA
3 cellular response to DNA damage stimulus GO:0006974 9.92 ABL1 ATM BRCC3 CHEK2 MYC
4 phosphorylation GO:0016310 9.91 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3
5 regulation of cell proliferation GO:0042127 9.85 ABL1 CDKN1B JAK1 JAK3
6 DNA repair GO:0006281 9.77 ABL1 ATM BRCC3 CHEK2 SMARCB1
7 protein autophosphorylation GO:0046777 9.76 ABL1 ATM CHEK2 JAK1
8 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.75 MTCP1 TCL1A VEGFA
9 DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest GO:0006977 9.67 ATM CDKN1B CHEK2
10 intrinsic apoptotic signaling pathway in response to DNA damage GO:0008630 9.65 ABL1 ATM CHEK2
11 replicative senescence GO:0090399 9.61 ATM CHEK2
12 interleukin-15-mediated signaling pathway GO:0035723 9.6 JAK1 JAK3
13 positive regulation of response to DNA damage stimulus GO:2001022 9.59 ATM MYC
14 cellular response to angiotensin GO:1904385 9.58 MYC NFKB1
15 signal transduction in response to DNA damage GO:0042770 9.57 ABL1 CHEK2
16 interleukin-2-mediated signaling pathway GO:0038110 9.56 JAK1 JAK3
17 positive regulation of mitochondrial membrane potential GO:0010918 9.54 MYC TCL1A
18 interleukin-21-mediated signaling pathway GO:0038114 9.51 JAK1 JAK3
19 peptidyl-tyrosine autophosphorylation GO:0038083 9.5 ABL1 JAK1 JAK3
20 cell cycle arrest GO:0007050 9.46 ABL1 ATM CDKN1B MYC
21 ovarian follicle development GO:0001541 9.43 ATM MYC VEGFA
22 interleukin-9-mediated signaling pathway GO:0038113 9.4 JAK1 JAK3
23 transmembrane receptor protein tyrosine kinase signaling pathway GO:0007169 9.26 ABL1 CD7 JAK1 JAK3
24 DNA damage induced protein phosphorylation GO:0006975 8.8 ABL1 ATM CHEK2
25 cell cycle GO:0007049 10.03 ATM BRCC3 CDKN1B CHEK2 SMARCB1
26 protein phosphorylation GO:0006468 10.02 ABL1 ATM CHEK2 JAK1 JAK3
27 negative regulation of apoptotic process GO:0043066 10.01 CDKN1B MYC NFKB1 TCL1A VEGFA

Molecular functions related to T-Cell Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase activity GO:0004672 9.65 ABL1 ATM CHEK2 JAK1 JAK3
2 protein phosphatase binding GO:0019903 9.33 CDKN1B JAK1 JAK3
3 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.13 ABL1 JAK1 JAK3
4 kinase activity GO:0016301 9.1 ABL1 ATM CDKN1B CHEK2 JAK1 JAK3

Sources for T-Cell Prolymphocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....